ASLAN rakes in $43 mln

By Iris Dorbian — 1 month ago

Singapore-based biotech company ASLAN Pharmaceuticals has raised $43 million in Series C funding. The investors included new backer MVP Capital Partners.

Continue

Israeli biotech company KAHR rakes in $12 mln Series B

By Iris Dorbian — 2 months ago

Israeli biotech company KAHR Medical Ltd has secured $12 million in Series B funding. The investors in this round were Korea Investment Partners, Mirae Asset Venture Investment, DSC Investment and return backer Flerie Invest AB. RM Global Partners advised KAHR on the transaction.

Continue

Biotech startup Kallyope snags $44 mln Series A

By Iris Dorbian — 2 months ago

New York City-based Kallyope Inc, a biotech company focused on “harnessing the potential of the gut-brain axis,” has launched with $44 million in Series A funding. The company’s investors include Lux Capital, Polaris Partners, The Column Group, Illumina Inc and Alexandria Venture Investments.

Continue

Prosetta picks up about $31 mln

By Iris Dorbian — 2 months ago

San Francisco-based biotech company Prosetta Biosciences Inc has closed about $31 million in a Series D private placement. The investors included Alger Management and Takeda Pharmaceutical Company Limited. T.R. Winston & Company served as the placement agent and financial advisor to Prosetta in the transaction.

Continue

ASLAN Pharmaceuticals nets $34 mln Series C

By Iris Dorbian — 2 months ago

Singapore-based biotech company ASLAN Pharmaceuticals has raised $34 million in Series C funding. Accuron Technologies Limited, a Temasek Holdings subsidiary, led the round. Other investors included Tianda Pharmaceuticals Limited, Haitong International, Morningside, Bioveda, Cenova and Sagamore Bioventures.

Continue

Atreca grabs $56 mln Series A

By Iris Dorbian — 3 months ago

Redwood City, California-based biotech company Atreca Inc has closed $56 million in Series A funding. The investors included the Bill & Melinda Gates Foundation, Mission Bay Capital and GlaxoSmithKline. Brookline Group LLC was the placement agent. PRESS RELEASE REDWOOD CITY, Calif.–(BUSINESS WIRE)–Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding […]

Continue

Turnstone rakes in $11.3 mln Series A in Versant-led round

By Iris Dorbian — 3 months ago

Turnstone Biologics Inc, a biotech company focused on developing novel oncolytic viral immunotherapies for cancer, has closed $11.3 million in Series A funding. Versant Ventures led the round. In addition to the funding, the company has named Dr. Sammy J. Farah as CEO and Dr. Brian D. Lichty as chief technology officer while adding Dr. Jerel Davis and Dr. Brad Bolzon, a partner and managing director at Versant Ventures respectively, to its board of directors.

Continue

VC-backed Edge Therapeutics goes public

By Iris Dorbian — 4 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has debuted its IPO after pricing its over 7.3 million shares at $11 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “EDGE.” Leerink Partners and Credit Suisse are serving as the lead underwriters. Edge Therapeutics’ backers included Venrock, Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures.

Continue

BD Life Sciences acquires VC-backed Cellular Research

By Iris Dorbian — 6 months ago

BD Life Sciences has closed its buy of Menlo Park, California-based Cellular Research Inc, a biotechnology research and development company. No financial terms were disclosed. Cellular Research’s backers included Tactics II Stem Cell Ventures, Equity Group Investments LLC, Sixth Floor Investors LP and G Force Investments LLC.

Continue

Swiss biotech company Kuros grabs funding

By Iris Dorbian — 6 months ago

Swiss biotech company Kuros Biosurgery AG has raised CHF15M (approximately over $15.35 million) in funding. LifeCare Partners and LSP Life Sciences Partners led the round with participation from other investors that included Omega Funds, VI Partners (via Venture Incubator) and The Swiss Helvetia Fund Inc. In addition to the funding, Dr. Gerhard Ries, managing partner of LifeCare Partners, Dr. Jörg Neermann, a partner at LSP and Dominik Ellenrieder have been added to the Kuros board.

Continue

Biotech company Avitide pulls in Series C funds

By Iris Dorbian — 6 months ago

Lebanon, New Hampshire-based biotech company Avitide Inc has secured an undisclosed amount of Series C funding. NeoMed Management led the round with participation from previous backers Polaris Partners, OrbiMed Advisors, SV Life Sciences and Borealis Ventures. In addition to the funding, Claudio Nessi of NeoMed has been added to Avitide’s board of directors.

Continue

Immune Pharmaceuticals racks up $21.5 mln

By Iris Dorbian — 6 months ago

Immune Pharmaceuticals has raised up to $21.5 million in financing from Hercules Technology Growth Capital and Discover Growth Fund. Roth Capital Partners and Chardan Capital Markets served as placement agents on the financing from Discover while TriPoint Global Equities was a placement agent on the Hercules financing. Based in New York and Israel, Immune Pharmaceuticals is a biotech company that is developing antibody therapeutics for patients with inflammatory diseases and cancer.

Continue

Ra Pharmaceuticals racks up $58.5 mln Series B

By Iris Dorbian — 7 months ago

Cambridge, Massachusetts-based biotech company Ra Pharmaceuticals has closed $58.5 million in Series B funding. RA Capital Management, Novo Ventures and Lightstone Ventures led the round with participation from other investors that included Rock Springs Capital Limulus Venture Partners, New Enterprise Associates, Novartis Venture Fund, Morgenthaler Ventures and Amgen Ventures. In conjunction with the funding, Rajeev Shah of RA Capital and Peter Tuxen Bisgaard of Novo Ventures (US) Inc have been added to Ra Pharma’s board of directors.

Continue

Immunocore racks up $320 mln

By Iris Dorbian — 7 months ago

UK-based biotech company Immunocore Limited has closed $320 million in funding. The investors included Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company and RTW Investments. Credit Suisse served as advisor to Immunocore on the transaction.

Continue